Radiation Recall Pneumonitis Caused by Erlotinib after Palliative Definitive Radiotherapy

Onkologie ◽  
2012 ◽  
Vol 35 (4) ◽  
pp. 191-194 ◽  
Author(s):  
Cem Onal ◽  
Huseyin Abali ◽  
Zafer Koc ◽  
Sibel Kara
Author(s):  
Douglas Clark ◽  
Dron Gauchan ◽  
Ryan Ramaekers ◽  
Max Norvell ◽  
Mehmet Sitki Copur

2019 ◽  
Vol 14 (10) ◽  
pp. e224-e226 ◽  
Author(s):  
Mateo Sanchis-Borja ◽  
Antoine Parrot ◽  
Déborah Sroussi ◽  
Eleonor Rivin del Campo ◽  
Vincent Fallet ◽  
...  

2020 ◽  
Vol 15 (10) ◽  
pp. e160-e162 ◽  
Author(s):  
Yan-Yang Wang ◽  
Xing-Cang Tian ◽  
Li Zhu ◽  
Xue-Hong Bai ◽  
Ren Zhao

Haigan ◽  
2010 ◽  
Vol 50 (7) ◽  
pp. 937-941
Author(s):  
Minoru Inomata ◽  
Toshimichi Miya ◽  
Yutaka Kokubo

2018 ◽  
Vol 88 (2) ◽  
Author(s):  
Elena Bargagli ◽  
Viola Bonti ◽  
Alessandra Bindi ◽  
Vieri Scotti ◽  
Massimo Pistolesi ◽  
...  

Patients treated for lung cancer may develop lung toxicity induced by chemotherapy (DILD), radiation or combined radiation recall pneumonitis. In the literature, some cases of immune-mediated pneumonitis have been reported associated with immunotherapy. The clinical and radiologic features of interstitial lung toxicity are unspecific, dyspnoea and dry cough are the most common symptoms while the most frequent radiological pattern is the cryptogenic organizing pneumonia (COP). Why only some individuals treated with these drugs develop interstitial lung toxicity is unclear.In the last few years some studies have reported the utility of KL 6 for the evaluation of DILD. The treatment is based on high doses of systemic steroids or immune suppressor. In this study we report severe interstitial lung damage in patients treated with different anti-blastic, immune and radiation therapies. Treated with surgery, chemotherapy, immuno and radiotherapy for lung cancer, they unfortunately died of severe DILD.


2021 ◽  
Author(s):  
Kanako Shinada ◽  
Shuji Murakami ◽  
Daisaku Yoshida ◽  
Haruhiro Saito

Sign in / Sign up

Export Citation Format

Share Document